Excision of nucleoside analogs from DNA by p53 protein, a potential cellular mechanism of resistance to inhibitors of human immunodeficiency virus type 1 reverse transcriptase

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 4, 2005, Pages 1576-1579

  Bakhanashvili, Mary ^a,b   Novitsky, Elena ^a   Rubinstein, Ethan ^a   Levy, Itzchak ^a   Rahav, Galia ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DNA HYBRID; DNA POLYMERASE; EXONUCLEASE; NUCLEOSIDE ANALOG; PROTEIN P53; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOPLASM; DNA REPLICATION; DRUG RESISTANCE; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOPRECIPITATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RNA TRANSCRIPTION; VIRUS MUTATION;

ANTI-HIV AGENTS; CELL LINE, TUMOR; CYTOPLASM; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; NUCLEOSIDES; REVERSE TRANSCRIPTASE INHIBITORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 16244423293     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.4.1576-1579.2005     Document Type: Article

References (27)

1. Achanta, G., H. Pelicano, L. Feng, W. Plunkett, and P. Huang. 2001. Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage. Cancer Res. 61:8723-8729.
2. Arion, D., and M. A. Parniak. 1999. HIV resistance to zidovudine: the role of pyrophosphorolysis. Drug Resist. Updates 2:91-95.
3. Bakhanashvili, M. 2001. Exonucleolytic proofreading by p53 protein. Eur. J. Biochem. 268:2047-2254.
4. Bakhanashvili, M. 2001. p53 enhances the fidelity of DNA synthesis by human immunodeficiency virus type 1 reverse transcriptase. Oncogens 20:7635-7644.
5. Bakhanashvili, M., and A. Hizi. 1992. Fidelity of the reverse transcriptase of human immunodeficiency virus type 2. FEBS Lett. 306:151-156.
6. Bakhanashvili, M., and A. Hizi. 1992. Fidelity of the RNA-dependent DNA synthesis exhibited by the reverse transcriptases of human immunodeficiency virus types 1 and 2 and of murine leukemia virus: mispair extension frequencies. Biochemistry 31:9393-9398.
7. Bakhanashvili, M., E. Novitsky, G. Lilling, and G. Rahav. 2004. p53 in cytoplasm may enhance the accuracy of DNA synthesis by human immunodeficiency virus type 1 reverse transcriptase. Oncogene 23:6890-6899.
8. Boyer, P. L., S. G. Sarafianos, E. Arnold, and S. Hughes. 2001. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J. Virol. 75:4832-4842.
9. Coffin, J. M. 1986. Genetic variation in AIDS viruses. Cell 46:1-4.
10. De Clerq, E. 1992. HIV inhibitors targeted at the reverse transcriptase. AIDS Res. Hum. Retrovir. 8:119-134.
11. Feng, L., G. Achanta, H. Pelicano, W. Zhang, W. Plunkett, and P. Huang. 2000. Role of p53 in cellular response to anticancer nucleoside analog-induced DNA damage. Int. J. Mol. Med. 5:597-604.
12. Huang, P. 1998. Excision of mismatched nucleotides from DNA: a potential mechanism for enhancing DNA replication fidelity by the wild-type p53 protein. Oncogene 17:261-270.
13. Ji, J., and L. A. Loeb. 1992. Fidelity of HIV-1 reverse transcriptase copying RNA in vitro. Biochemistry 30:7566-7572.
14. Lilling, G., E. Novitsky, Y. Sidi, and M. Bakhanashvili. 2003. p53-associated 3′→5′ exonuclease activity in nuclear and cytoplasmic compartments of cells. Oncogene 22:233-245.
15. Melle, C., and H. Nasheuer. 2002. Physical and functional interactions of the tumor suppressor protein p53 and DNA polymerase α-primase. Nucleic Acids Res. 30:1493-1499.
16. Menendez-Arias, L. 2002. Molecular basis of fidelity of DNA synthesis and nucleotide specificity of retroviral reverse transcriptases. Prog. Nucleic Acid Res. Mol. Biol. 71:91-147.
17. Meyer, P. R., S. E. Matsuura, A. M. Mian, A. G. So, and W. A. Scott. 1999. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol. Cell 4:35-43.
18. Mummenbrauer, T., F. Janus, B. Muller, L. Wiesmuller, W. Deppert, and F. Grosse. 1996. p53 protein exhibits 3′-to-5′ exonuclease activity. Cell 85:1089-1099.
19. Perrino, F. W., B. D. Preston, L. L. Sandell, and L. A. Loeb. 1989. Extension of mismatched 3′ termini of DNA is a major determinant of the infidelity of human immunodeficiency virus type 1 reverse transcriptase. Proc. Natl. Acad. Sci. USA 86:8343-8347.
20. Ragimov, N., A. Krauskopf, N. Navot, V. Rotter, M. Oren, and Y. Aloni. 1993. Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif. Oncogene 8:1183-1193.
21. Roberts, J. D., K. Bebenek, and T. A. Kunkel. 1989. The accuracy of reverse transcriptase from HIV-1. Science 242:1171-1173.
22. Shakked, Z., M. Yavnilovitch, A. J. Kalb, N. Kessler, R. Wolkowicz, V. Rotter, and T. E. Haran. 2002. DNA binding and 3′-5′ exonuclease activity in the murine alternatively-spliced p53 protein. Oncogene 21:5117-5126.
23. Shevelev, I. V., and U. Hubscher. 1990. The 3′→5′ exonucleases. Nat. Rev. 3:1-12.
24. Skalski, V., Z. Lin, B. Y. Choi, and K. R. Brown. 2000. Substrate specificity of the p53-associated 3′→5′ exonuclease. Oncogene 19:3321-3329.
25. Sluis-Cremer, N., D. Arion, and M. A. Parniak. 2000. Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs). Cell. Mol. Life Sci. 57:1408-1422.
26. Svarovskaia, E. S., S. R. Cheslock, W. Zhang, W. Hu, and V. K. Pathak. 2003. Retroviral mutation rates and reverse transcriptase fidelity. Front. Biosci. 8: d117-d134.
27. Zhou, Y., G., Achanta, H. Pelicano, V. Gandhi, W. Plunkett, and P. P. Huang. 2002. Action of (E)-2′ deoxy-2′-(fluoromethylene) cytidine on DNA metabolism: incorporation, excision, and cellular response. Mol. Pharmacol. 61:222-229.